Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia is a serious condition requiring effective management.
• Current treatments for hyperkalemia have limitations.
• Sodium zirconium cyclosilicate (SZC) offers a novel therapeutic approach.

Purpose of the Study:

• To evaluate the efficacy and safety of SZC in treating hyperkalemia in adults.
• To assess the long-term maintenance of normokalemia with SZC therapy.

Main Methods:

• Two multinational, phase III studies were conducted in adult patients with hyperkalemia.
• Patients received varying doses of SZC (10g TID, 5g QD, 10g QD).
• Serum potassium levels were monitored during acute treatment (48h) and maintenance therapy (≤28 days, ≤12 months).

Main Results:

• SZC rapidly lowered serum potassium to normal levels within 48 hours.
• Once-daily SZC (5g and 10g) maintained normokalemia for up to 28 days.
• Beneficial effects were consistent across patient subgroups, including those with CKD, diabetes, and heart failure.
• Long-term treatment (≤12 months) demonstrated sustained efficacy and consistent safety.
• SZC was generally well-tolerated, with a safety profile similar to placebo and a low incidence of hypokalemia.

Conclusions:

• Sodium zirconium cyclosilicate is an effective and well-tolerated treatment for managing hyperkalemia in adults.
• SZC provides rapid and sustained potassium reduction, maintaining normokalemia.
• Its consistent efficacy and safety across various patient populations make it a promising therapeutic option.